肺癌被认为是最常见的癌症。尽管Ramucirumab抗体是肺癌的二线治疗方法,高的间质液压力限制了抗体的性能。这样,伊马替尼是一种降低间质液压力的化疗药物。到目前为止,不幸的是,尚未报道Ramucirumab和伊马替尼在一种纳米系统中用于癌症治疗.为了弥补这个缺点,本文旨在设计一种负载伊马替尼并附着在雷木鲁单抗上的壳聚糖纳米载体,用于选择性结合A549。因此,本文旨在开发一种用于非小细胞肺癌(NSCLC)治疗的聚合物纳米系统。首先,合成了壳聚糖聚乙二醇纳米颗粒,装载伊马替尼,然后使用Ramucirumab靶向。之后,CS-PEG-Ab-Im的FTIR,TEM,DLS,zeta电位,和TGA技术的特点。CS-PEG-Ab-Im的大小为25-30nm,其表面电荷为13.1mV,CS-PEG-Ab-Im的形状为近球形和圆柱形。使用A549细胞系评估CS-PEG-Ab-Im的治疗潜力。根据得到的结果,在使用IC50浓度的CS-PEG-Ab-Im(100纳摩尔)处理A549细胞48小时后,细胞活力为48%。此外,细胞凋亡和细胞周期停滞百分比分别增加3和6倍,分别,与游离伊马替尼相比。此外,在酸性介质中,伊马替尼从CS-PEG-Ab-Im中的释放速率在1小时内为17%,表明伊马替尼在天然培养基中释放的五倍。最终,流式细胞术的结果表明,纳米系统对游离伊马替尼和CS-PEG-Ab的凋亡作用更大。此外,细胞阻滞结果显示CS-PEG-Ab-Im,并导致G1细胞阻滞8.17%。因此,由此可以得出结论,CS-PEG-Ab-Im可以作为治疗NSCLC的理想纳米系统。
Lung cancer is known as the most common cancer. Although the Ramucirumab antibody is a second-line treatment for lung cancer, the high interstitial fluid pressure limits the antibody\'s performance. In this way, Imatinib is a chemotherapeutic drug to reduce the interstitial fluid pressure. Up to now, unfortunately, both Ramucirumab and imatinib have not been reported in one nanosystem for cancer therapy. To fulfill this shortcoming, this paper aims to design a chitosan nanocarrier that loads imatinib and attaches to Ramucirumab for selective bonding to A549. Therefore, this paper aims to develop a polymeric nanosystem for non-small cell lung cancer (NSCLC) treatment. In first, the chitosan polyethylene glycol nanoparticle is synthesized, loaded with imatinib, and then targeted using Ramucirumab. Afterwards, the CS-PEG-Ab-Im by FTIR, TEM, DLS, zeta potential, and TGA techniques are characterized. The size of CS-PEG-Ab-Im was 25-30 nm, its surface charge was 13.1 mV, and the shape of CS-PEG-Ab-Im was nearly spherical and cylindrical. The therapeutic potential of CS-PEG-Ab-Im was assessed using the A549 cell line. According to the obtained results, the cell viability was 48% after 48 h of treatment of A549 cells using the IC50 concentration of CS-PEG-Ab-Im (100 nanomolar). Moreover, the apoptosis and cell cycle arrest percentages were increased by 3 and 6 times, respectively, as compared to free imatinib. Furthermore, the release rate of imatinib from CS-PEG-Ab-Im in an acidic medium was 17% during 1 h, indicating five times the imatinib release in the natural medium. Eventually, the result of flow cytometry indicates the more apoptotic effect of nanosystem to free imatinib and CS-PEG-Ab. Besides, cell arresting result exhibits the CS-PEG-Ab-Im and causes cell arrested at G1 by %8.17. Thus, it can be concluded that CS-PEG-Ab-Im can be an ideal nanosystem in NSCLC treatment.